限制性与宽松输血策略对急性心肌梗死合并贫血患者主要心血管事件的影响:REALITY随机临床试验
REALITY试验在法国和西班牙35家医院纳入668例心肌梗死且血红蛋白7-10 g/dL患者,随机接受限制性(血红蛋白≤8 g/dL触发输血)或宽松性(≤10 g/dL触发)策略。30天主要心血管不良事件(MACE)发生率限制性组11.0% vs 宽松性组14.0%,相对风险0.79(单侧97.5%CI 0.00-1.19),满足预设非劣效界值1.25,但置信区间包含可能临床重要的危害。
要点
- 限制性输血策略在30天MACE上非劣于宽松策略,但置信区间上限接近非劣效界值。
- 限制性组输血比例35.7%,宽松组99.7%,限制性策略显著减少输血暴露。
- 全因死亡限制性组5.6% vs 宽松组7.7%,需结合置信区间解读。
核心结论
- 在急性心肌梗死合并贫血患者中,限制性输血策略30天MACE发生率非劣于宽松策略。
- 但相对风险的置信区间包含可能临床重要的危害,需谨慎解读非劣效结论。
研究设计与样本
- 开放标签、非劣效、随机临床试验,在法国和西班牙35家医院进行。
- 纳入668例心肌梗死且血红蛋白7-10 g/dL患者,随机分为限制性组342例和宽松性组324例。
- 主要终点为30天MACE复合终点(全因死亡、卒中、再发心梗或紧急血运重建)。
- 非劣效界值为主要终点相对风险的单侧97.5%CI上限小于1.25。
主要发现
- 30天MACE发生率限制性组11.0%(95%CI 7.5%-14.6%)vs 宽松组14.0%(95%CI 10.0%-17.9%),差值-3.0%(95%CI -8.4%至2.4%)。
- 主要终点相对风险0.79(单侧97.5%CI 0.00-1.19),满足非劣效标准。
- 全因死亡限制性组5.6% vs 宽松组7.7%;再发心梗2.1% vs 3.1%;紧急血运重建1.5% vs 1.9%;非致命缺血性卒中两组均为0.6%。
- 限制性组122例(35.7%)接受输血,共输注342单位红细胞;宽松组323例(99.7%)接受输血,共输注758单位。
关键数值与推荐
- 限制性策略输血触发阈值:血红蛋白≤8 g/dL。
- 宽松性策略输血触发阈值:血红蛋白≤10 g/dL。
- 非劣效判定标准:主要终点相对风险的单侧97.5%CI上限<1.25。
临床怎么用
- 对于急性心肌梗死合并贫血(血红蛋白7-10 g/dL)患者,可考虑限制性输血策略以减少输血暴露。
- 临床决策需个体化,因非劣效界值附近存在潜在危害的不确定性。
局限性
- 开放标签设计可能引入偏倚。
- 主要终点置信区间上限接近非劣效界值,不能排除临床重要危害。
- 30天随访时间较短,长期结局未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal transfusion strategy in patients with acute myocardial infarction and anemia is unclear. OBJECTIVE: To determine whether a restrictive transfusion strategy would be clinically noninferior to a liberal strategy. DESIGN, SETTING, AND PARTICIPANTS: Open-label, noninferiority, randomized trial conducted in 35 hospitals in France and Spain including 668 patients with myocardial infarction and hemoglobin level between 7 and 10 g/dL. Enrollment could be considered at any time during the index admission for myocardial infarction. The first participant was enrolled in March 2016 and the last was enrolled in September 2019. The final 30-day follow-up was accrued in November 2019. INTERVENTIONS: Patients were randomly assigned to undergo a restrictive (transfusion triggered by hemoglobin ≤8; n = 342) or a liberal (transfusion triggered by hemoglobin ≤10 g/dL; n = 324) transfusion strategy. MAIN OUTCOMES AND MEASURES: The primary clinical outcome was major adverse cardiovascular events (MACE; composite of all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization prompted by ischemia) at 30 days. Noninferiority required that the upper bound of the 1-sided 97.5% CI for the relative risk of the primary outcome be less than 1.25. The secondary outcomes included the individual components of the primary outcome. RESULTS: Among 668 patients who were randomized, 666 patients (median [interquartile range] age, 77 [69-84] years; 281 [42.2%] women) completed the 30-day follow-up, including 342 in the restrictive transfusion group (122 [35.7%] received transfusion; 342 total units of packed red blood cells transfused) and 324 in the liberal transfusion group (323 [99.7%] received transfusion; 758 total units transfused). At 30 days, MACE occurred in 36 patients (11.0% [95% CI, 7.5%-14.6%]) in the restrictive group and in 45 patients (14.0% [95% CI, 10.0%-17.9%]) in the liberal group (difference, -3.0% [95% CI, -8.4% to 2.4%]). The relative risk of the primary outcome was 0.79 (1-sided 97.5% CI, 0.00-1.19), meeting the prespecified noninferiority criterion. In the restrictive vs liberal group, all-cause death occurred in 5.6% vs 7.7% of patients, recurrent myocardial infarction occurred in 2.1% vs 3.1%, emergency revascularization prompted by ischemia occurred in 1.5% vs 1.9%, and nonfatal ischemic stroke occurred in 0.6% of patients in both groups. CONCLUSIONS AND RELEVANCE: Among patients with acute myocardial infarction and anemia, a restrictive compared with a liberal transfusion strategy resulted in a noninferior rate of MACE after 30 days. However, the CI included what may be a clinically important harm. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02648113.
引用
- Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA. 2021. PMID: 33560322. doi:10.1001/jama.2021.0135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。